Role of binary toxin in the outcome of Clostridium difficile infection in a non-027 ribotype setting

Epidemiology and Infection

Volumn 144, Issue 2, 2016, Pages 268-273

  Reigadas, E ^a,b,c   Alcala L ^a,c,d   Marin M ^a,b,c,d   Martin A ^a,c   Iglesias, C ^a,b,c,d   Bouza, E ^a,b,c,d  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b SCHOOL OF MEDICINE   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Binary toxin; Clostridium difficile infection; outcome; recurrence; ribotype; severe

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CLOSTRIDIUM DIFFICILE BINARY TOXIN; CLOSTRIDIUM TOXIN; PROTON PUMP INHIBITOR; UNCLASSIFIED DRUG; ACTIN-SPECIFIC ADP-RIBOSYLTRANSFERASE, CLOSTRIDIUM; BACTERIAL PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ADULT; AGED; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BT GENE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG TREATMENT FAILURE; EPIDEMIOLOGICAL DATA; FEMALE; GENE IDENTIFICATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR DIAGNOSIS; MORTALITY; MULTIPLEX POLYMERASE CHAIN REACTION; NONHUMAN; OUTCOME ASSESSMENT; PEPTOCLOSTRIDIUM DIFFICILE; PROSPECTIVE STUDY; RECURRENT INFECTION; RIBOTYPING; SYMPTOM; ADOLESCENT; CHILD; CLOSTRIDIUM INFECTIONS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; GENETICS; METABOLISM; MICROBIOLOGY; MIDDLE AGED; PHYSIOLOGY; PRESCHOOL CHILD; SPAIN; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADP RIBOSE TRANSFERASES; ADULT; AGED; AGED, 80 AND OVER; BACTERIAL PROTEINS; CHILD; CHILD, PRESCHOOL; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLEX POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; SPAIN; YOUNG ADULT;

EID: 84949535876     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S095026881500148X     Document Type: Article

References (35)

1. Dubberke ER, Olsen MA. Burden of Clostridium difficile on the healthcare system. Clinical Infectious Diseases 2012; 55 (Suppl. 2): S88-92.
2. Wiegand PN, et al. Clinical and economic burden of Clostridium difficile infection in Europe: A systematic review of healthcare-facility-acquired infection. Journal of Hospital Infection 2012; 81: 1-14.
3. Asensio A, et al. Cost of Clostridium difficile associated diarrhoea in Spain [in Spanish]. Revista Española de Salud Pública 2013; 87: 25-33.
4. Miller MA, et al. Morbidity, mortality, and healthcare burden of nosocomial Clostridium difficile-associated diarrhoea in Canadian hospitals. Infection Control & Hospital Epidemiology 2002; 23: 137-140.
5. Henrich TJ, et al. Clinical risk factors for severe Clostridium difficile-associated disease. Emerging Infectious Diseases 2009; 15: 415-422.
6. Hensgens MP, et al. Predicting a complicated course of Clostridium difficile infection at the bedside. Clinical Microbiology and Infection 2014; 20: 301-308.
7. Lungulescu OA, et al. CSI: A severity index for Clostridium difficile infection at the time of admission. Journal of Hospital Infection 2011; 79: 151-154.
8. McFarland LV, et al. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infection Control & Hospital Epidemiology 1999; 20: 43-50.
9. Voth DE, Ballard JD. Clostridium difficile toxins: mechanism of action and role in disease. Clinical Microbiology Reviews 2005; 18: 247-263.
10. Goncalves C, et al. Prevalence and characterization of a binary toxin (actin-specific ADP-ribosyltransferase) from Clostridium difficile. Journal of Clinical Microbiology 2004; 42: 1933-1939.
11. Barbut F, et al. Prospective study of Clostridium difficile infections in Europe with phenotypic and genotypic characterisation of the isolates. Clinical Microbiology and Infection 2007; 13: 1048-1057.
12. Warny M, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366: 1079-1084.
13. Kuijper EJ, et al. Emergence of Clostridium difficileassociated disease in North America and Europe. Clinical Microbiology and Infection 2006; 12 (Suppl. 6): 2-18.
14. Cohen SH, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infection Control & Hospital Epidemiology 2010; 31: 431-455.
15. Charlson ME, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of Chronic Diseases 1987; 40: 373-383.
16. McCabe WR, Jackson GG. Gram-negative bacteremia: I. Etiology and ecology. Archives of Internal Medicine 1962; 110: 847-855.
17. Persson S, et al. New multiplex PCR method for the detection of Clostridium difficile toxin A (tcdA) and toxin B (tcdB) and the binary toxin (cdtA/cdtB) genes applied to a Danish strain collection. Clinical Microbiology and Infection 2008; 14: 1057-1064.
18. Lemee L, et al. Multiplex PCR targeting tpi (triose phosphate isomerase), tcdA (toxin A), and tcdB (toxin B) genes for toxigenic culture of Clostridium difficile. Journal of Clinical Microbiology 2004; 42: 5710-5714.
19. Stubbs SL, et al. PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes. Journal of Clinical Microbiology 1999; 37: 461-463.
20. Popoff MR, et al. Actin-specific ADP-ribosyltransferase produced by a Clostridium difficile strain. Infection and Immunity 1988; 56: 2299-2306.
21. Stubbs S, et al. Production of actin-specific ADPribosyltransferase (binary toxin) by strains of Clostridium difficile. FEMS Microbiology Letters 2000; 186: 307-312.
22. McDonald LC, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. New England Journal of Medicine 2005; 353: 2433-2441.
23. Loo VG, et al. A predominantly clonal multiinstitutional outbreak of Clostridium difficile-associated diarrhoea with high morbidity and mortality. New England Journal of Medicine 2005; 353: 2442-2449.
24. Barbut F, et al. Clinical features of Clostridium difficile-associated infections and molecular characterization of strains: results of a retrospective study, 2000-2004. Infection Control & Hospital Epidemiology 2007; 28: 131-139.
25. Alcala L, et al. The undiagnosed cases of Clostridium difficile infection in a whole nation: where is the problem? Clinical Microbiology and Infection 2012; 18: E204-213.
26. Davies KA, et al. Underdiagnosis of Clostridium difficile across Europe: The European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID). Lancet Infectious Diseases 2014; 14: 1208-1219.
27. Alcala L, et al. and the Spanish Clostridium difficile Study Group. Multicentre study of Clostridium difficile infection in Spain (studies II and III): updating the evolution of underdiagnosis of Clostridium difficile infection in a whole nation. 24th European Congress of Clinical Microbiology and Infectious Diseases Barcelona, Spain, 2014.
28. Goorhuis A, et al. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clinical Infectious Diseases 2008; 47: 1162-1170.
29. Walk ST, et al. Clostridium difficile ribotype does not predict severe infection. Clinical Infectious Diseases 2012; 55: 1661-1668.
30. Sirard S, et al. Lack of association between clinical outcome of Clostridium difficile infections, strain type, and virulence-associated phenotypes. Journal of Clinical Microbiology 2011; 49: 4040-4046.
31. Barbut F, et al. Clinical features of Clostridium difficileassociated diarrhoea due to binary toxin (actin-specific ADP-ribosyltransferase)-producing strains. Journal of Medical Microbiology 2005; 54: 181-185.
32. Kim J, et al. Clinical and microbiologic characteristics of Clostridium difficile infection caused by binary toxin producing strain in Korea. Infection & Chemotherapy 2013; 45: 175-183.
33. Stewart DB, et al. Predicting recurrence of C. difficile colitis using bacterial virulence factors: binary toxin is the key. Journal of Gastrointestinal Surgery 2013; 17: 118-124 (discussion 124-115).
34. Goldenberg SD, French GL. Lack of association of tcdC type and binary toxin status with disease severity and outcome in toxigenic Clostridium difficile. Journal of Infection 2011; 62: 355-362.
35. Bacci S, et al. Binary toxin and death after Clostridium difficile infection. Emerging Infectious Diseases 2011; 17: 976-982.